Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Open accessThe DOI matches its Crossref record; 506 of the 506 references it cites were found in a registry or an index.
Abstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum ‘cocktail’ of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These authors trained a DL algorithm on a large dataset of known cancer-related compounds and their corresponding biological activity. As an output, novel compounds with high potential for future cancer treatment were obtained, demonstrating the ability of this method to discover new therapeutic candidates.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, the successful use of AI to identify novel compounds for the treatment of cancer has recently been reported by Gupta, R., et al. [21].”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–506 of 506
Improvement of Virtual Screening Results by Docking Data Feature Analysis
Arciniega, M., & Lange, O. F. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500028u · Cited by 34 · cited 1×
“D structural information of protein or target has been elucidated either through in vitro or in vivo experiments or through computational modeling [162, 163].”
BackgroundXu, R., & Wang, Q. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.06.027 · Cited by 34 · cited 1×
“Finally, validation of repurposed drugs is carried out through clinical trials, in vitro studies, and in vivo studies ◂ phenome-wide drug repositioning for schizophrenia and prediction of drug-target interactions, respectively [289, 290].”
MethodChemBoost: A Chemical Language Based Approach for Protein – Ligand Binding Affinity Prediction
Özçelik, R., Öztürk, H., Özgür, A., & Özkırımlı, E. (2020) · Molecular Informatics · doi:10.1002/minf.202000212 · Cited by 34
Xue, R., Liao, J., Shao, X., Han, K., Long, J., Shao, L., Ai, N., & Fan, X. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00238 · Cited by 33 · cited 1×
“Further, Xue et al. [143] integrated biomedical network topology with a DL algorithm to predict Drug-ADR correlation.”
MethodKong, Y., Bender, A., & Yan, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00300 · Cited by 33 · cited 1×
“Emerging evidence suggests the potential implementation of AI algorithms in LBVS such as identification of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone…”
BackgroundNegStacking: Drug−Target Interaction Prediction Based on Ensemble Learning and Logistic Regression
Yang, J., He, S., Zhang, Z., & Bo, X. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2968025 · Cited by 33
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., García-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 32
A novel protein descriptor for the prediction of drug binding sites
Jiang, M., Li, Z., Bian, Y., & Wei, Z. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3058-0 · Cited by 32 · cited 1×
“Jiang et al. 2019, using DeepAffinity, proposed a novel protein descriptor for identifying drug-target interaction, whereas Born et al. 2020 with the help of Deep Affinity, identified antiviral candidates for SARS-CoV-2 [319, 320].”
MethodPyQSAR: A Fast QSAR Modeling Platform Using Machine Learning and Jupyter Notebook
Kim, S., & Cho, K. (2018) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11638 · Cited by 31
Halder, A. K., & Cordeiro, M. N. D. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174191 · Cited by 31
Seifert, M. H. J. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci0496393 · Cited by 30
Pires, D. E. V., Veloso, W. N. D. P., Myung, Y., Rodrigues, C. H. M., Silk, M. A., Rezende, P. M., Silva, F., Xavier, J. S., Velloso, J. P. L., da Silveira, C. H., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa480 · Cited by 30
DTI-RCNN: New Efficient Hybrid Neural Network Model to Predict Drug–Target Interactions
Zheng, X., He, S., Song, X., Zhang, Z., & Bo, X. (2018) · Lecture notes in computer science · doi:10.1007/978-3-030-01418-6_11 · Cited by 30 · cited 1×
“For example, SNF-CVAE based on drug similarity network fusion identified promising therapeutic agents for Alzheimer’s disease (AD) and juvenile rheumatoid arthritis, whereas DTI-RCNN based on neural network algorithm and integrates long short-term memory predicts drug-target interactions [287, 288].”
BackgroundShin, W., Christoffer, C. W., Wang, J., & Kihara, D. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00163 · Cited by 29
Pérez‐Castillo, Y., Sotomayor-Burneo, S., Jimenes-Vargas, K., González, M., Cruz‐Monteagudo, M., Armijos‐Jaramillo, V., Cordeiro, M. N. D. S., Borges, F., Sánchez‐Rodríguez, A., & Tejera, E. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00343 · Cited by 29
Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases
Martin, P., Ding, J., Duffus, K., Gaddi, V. P., McGovern, A., Ray-Jones, H. F., Yarwood, A., Worthington, J., Barton, A. C., & Orozco, G. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214649 · Cited by 29 · cited 1×
“Finally, they demonstrated that 367 drugs were suitable for repositioning [378].”
BackgroundDrug repurposing against Parkinson's disease by text mining the scientific literature
Zhu, Y., Jung, W., Wang, F., & Che, C. (2020) · Library Hi Tech · doi:10.1108/lht-08-2019-0170 · Cited by 29 · cited 1×
“In addition, [475] proposed a drug repurposing strategy for PD by scanning scientific literature through an integration of knowledge representation learning and ML algorithms .”
BackgroundMETADOCK: A parallel metaheuristic schema for virtual screening methods
Imbernón, B., Cecilia, J. M., Pérez‐Sánchez, H., et al. (2017) · The International Journal of High Performance Computing Applications · doi:10.1177/1094342017697471 · Cited by 29 · cited 1×
“Moreover, different algorithms and tools have been developed for LBVS such as SwissSimilarity (http:// www. swiss simil arity. ch/) [198], METADOCK [199], Open-source platform [200], HybridSim-VS (http:// www. rcidm. org/ Hybri dSim-VS/) [201], PKRank [202], PyGOLD (http:// www. agkoch. de/) [203],…”
MethodCombating Diseases with Computational Strategies Used for Drug Design and Discovery
Makhouri, F. R., & Ghasemi, J. B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190121125106 · Cited by 29 · cited 1×
“Repositioning drugs might be successful due to the possibility of multiple-target involvement in multiple diseases [267–269].”
BackgroundGeauxDock: Accelerating Structure-Based Virtual Screening with Heterogeneous Computing
Fang, Y., Ding, Y., Feinstein, W. P., Koppelman, D. M., Moreno, J., Jarrell, M., Ramanujam, J., & Bryliński, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158898 · Cited by 29 · cited 1×
“…imio. udla. edu. ec/ comps core/) [172], PlayMolecule BindScope (PlayMol-ecule.org) [173], GeauxDock (http:// www. bryli nski. org/ geaux dock) [174], EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176], PL-PatchSurfer2 (http:// www. kihar alab. org/ plps2/) [177],…”
InfluentialShen, Y., Liu, T. “., Chen, J., Li, X., Liu, L., Shen, J., Wang, J., Zhang, R., Sun, M., Wang, Z., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900114 · Cited by 28
Krishna, S., Shukla, S., Lakra, A. D., Meeran, S. M., & Siddiqi, M. I. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.05.014 · Cited by 28 · cited 1×
“Apart from these mentioned studies number of literature validated the possible implementation of AI in LBVS, such as identification of HIV entry inhibitors and potent inhibitors of DNA methyltransferase [218, 219].”
BackgroundWatson, O. P., Cortés‐Ciriano, I., Taylor, A. R., & Watson, J. A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz293 · Cited by 28
Coupling Matched Molecular Pairs with Machine Learning for Virtual Compound Optimization
Turk, S., Merget, B., Rippmann, F., & Fulle, S. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00298 · Cited by 26 · cited 1×
“It has been observed that DNN can predict better than RF and GBM [103].”
BackgroundMGATRx: Discovering Drug Repositioning Candidates Using Multi-View Graph Attention
Yella, J., & Jegga, A. G. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3082466 · Cited by 26 · cited 1×
“Moreover, Yella and Jegga et al. 2020 constructed a model for drug repositioning using a multi-view graph attention approach known as MGATRx [280], whereas Yan et al. 2019 constructed a novel algorithm for drug repurposing based on a multisimilarity fusion approach known as BiRWDDA [281].”
MethodKochev, N. T., Avramova, S., & Jeliazkova, N. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0295-6 · Cited by 25
Xuan, P., Cui, H., Shen, T., Sheng, N., & Zhang, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01301 · Cited by 25
Introduction to Neural Networks for Signal Processing
Hu, Y. H., & Hwang, J. (2018) · CRC Press eBooks · doi:10.1201/9781315220413-1 · Cited by 25
Wang, Y., Dou, X., Jiang, L., Jin, H., Zhang, L., Zhang, L., & Liu, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.039 · Cited by 24 · cited 1×
“Different studies were conducted on cancer and leukemia through SBVS, such as the discovery of novel GSK-3β for treatment of acute myeloid leukemia [189], identification of novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer [190], identification of vascular…”
Toxicity prediction of small drug molecules of androgen receptor using multilevel ensemble model
Gupta, V. K., & Rana, P. S. (2019) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720019500331 · Cited by 24 · cited 1×
“The authors incorporated 1444 characteristics features of small molecules on 10,273 drugs in which 461 are considered as active and 9812 are inactive [333].”
BackgroundIDDkin: network-based influence deep diffusion model for enhancing prediction of kinase inhibitors
Shen, C., Luo, J., Ouyang, W., Ding, P., & Chen, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa1058 · Cited by 24
Dalabira, E., Viennas, E. S., Daki, E., Komianou, A., Bartsakoulia, M., Poulas, K. A., Κάτσιλα, Θ., Tzimas, G. E., & Patrinos, G. P. (2014) · Public Health Genomics · doi:10.1159/000365895 · Cited by 24
Halder, A. K., Giri, A. K., & Cordeiro, M. N. D. S. (2019) · Molecules · doi:10.3390/molecules24213909 · Cited by 24
Quantitative structure-activity relationships of antioxidant phenolic compounds.
Hoelz, L. V. B., Horta, B. A. C., Araújo, J. Q., et al. (2010) · Journal of chemical and pharmaceutical research · Cited by 24
Xiao, T., Qi, X., Chen, Y., & Jiang, Y. (2018) · Molecular Informatics · doi:10.1002/minf.201800031 · Cited by 23 · cited 1×
“The study integrated 0.5 M chemical compounds, and the models developed were evaluated by tenfold cross-validation [224].”
MethodInfluentialA novel artificial intelligence protocol to investigate potential leads for Parkinson's disease
Chen, Z., Zhao, L., Chen, H., Gong, J.-N., Chen, X., & Chen, C. Y. (2020) · RSC Advances · doi:10.1039/d0ra04028b · Cited by 23 · cited 3×
“In addition, [472] implemented molecular docking, AI-QSAR, and MD simulations to find inhibitors of the NLR family pyrin domain containing 3 (NLRP3), an inflammasome involved in PD pathogenesis.”
MethodXing, G., Liang, L., Deng, C., Hua, Y., Chen, X., Yang, Y., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00169 · Cited by 23
A machine learning and network framework to discover new indications for small molecules
Gilvary, C. M., Elkhader, J. A., Madhukar, N. S., Henchcliffe, C., Goncalves, M. D., & Elemento, O. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008098 · Cited by 23 · cited 2×
“…anti-inflammatory drugs on cisplatin, paclitaxel, and doxorubicin efficacy against cervix cancer cells using PrOCTOR, whereas Gilvary et al. 2020 identified the novel indications for 2,576 small molecules incorporated with 16 different drug features for PD and Type 2 diabetes [336, 337].”
MethodLigGrep: a tool for filtering docked poses to improve virtual-screening hit rates
Ha, E. J., Lwin, C. T., & Durrant, J. D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00471-2 · Cited by 23
A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments
Lagarde, N., Goldwaser, E., Pencheva, T., Jereva, D., Pajeva, I. K., Rey, J., Tufféry, P., Villoutreix, B. O., & Miteva, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184648 · Cited by 23
do Nascimento, A. C. A., Prudêncio, R. B. C., & Costa, I. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_17 · Cited by 22
Jang, G., Lee, T., Hwang, S., Park, C., Ahn, J., Seo, S., Hwang, Y., & Yoon, Y. (2018) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.09.015 · Cited by 22 · cited 1×
“For instance, Jang et al. 2018 developed PISTON (http:// datab io. gachon. ac. kr/ tools/ PISTON/), a tool that can predict drug side effects and drug indications, using NLP and topic modeling [89].”
MethodDiscovery of new GSK-3β inhibitors through structure-based virtual screening
Dou, X., Jiang, L., Wang, Y., Jin, H., Liu, Z., & Zhang, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.036 · Cited by 22 · cited 1×
“Likewise, Liu et al. 2017 discovered low toxicity O-GlcNAc transferase inhibitors, whereas Dou et al. [187] identified novel glycogen synthase kinase 3 beta (GSK-3β) inhibitors through SBVS [188].”
BackgroundLitfin, T., Zhou, Y., & Yang, Y. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw829 · Cited by 22 · cited 1×
“…EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176], PL-PatchSurfer2 (http:// www. kihar alab. org/ plps2/) [177], SPOT-ligand 2 (http:// sparks-lab. org/) [178], Gypsum-DL (https:// durra ntlab. pitt. edu/ gypsum-dl/) [179], and ENRI [180] have been developed for SBVS.”
InfluentialArtificial Intelligence-Based Application to Explore Inhibitors of Neurodegenerative Diseases
Deng, L., Zhong, W., Zhao, L., He, X., Lian, Z., Jiang, S., & Chen, C. Y. (2020) · Frontiers in Neurorobotics · doi:10.3389/fnbot.2020.617327 · Cited by 21 · cited 1×
“Similarly, [473] used molecular docking, AI, and MD simulations to discover inhibitors of Galectin-3 a protein implicated for neuroinflammation in HD.”
MethodYousefian-Jazi, A., Sung, M. K., Lee, T., Hong, Y., Choi, J. K., & Choi, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-69790-6 · Cited by 21 · cited 1×
“Moreover, [465] used a CNN trained on an extensive GWAS data set to find novel risk single nucleotide polymorphisms and genes associated with ALS.”
MethodSugaya, N. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5003262 · Cited by 21 · cited 1×
“Likewise, Sugaya et al. [137] created a ligand-efficiency-driven support vector regression model to ascertain the biological activity of various chemical compounds.”
BackgroundBiRWDDA: A Novel Drug Repositioning Method Based on Multisimilarity Fusion
Yan, C., Wang, W., Zhang, G., Wang, J., & Patel, A. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2019.0063 · Cited by 21 · cited 1×
“Moreover, Yella and Jegga et al. 2020 constructed a model for drug repositioning using a multi-view graph attention approach known as MGATRx [280], whereas Yan et al. 2019 constructed a novel algorithm for drug repurposing based on a multisimilarity fusion approach known as BiRWDDA [281].”
MethodLi, Z., Yao, Y., Cheng, X., Chen, Q., Zhao, W., Ma, S., Li, Z., Zhou, H., Li, W., & Teng, F. (2021) · iScience · doi:10.1016/j.isci.2021.102148 · Cited by 21 · cited 2×
“Likewise, Li et al. 2020 constructed a computational framework of host-based drug repurposing for broad-spectrum antivirals against RNA virus.”
BackgroundGupta, R., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117912 · Cited by 20 · cited 1×
“For instance, [466] applied a combination of VS, ML, and molecular docking to find class 1 and class IIb histone dea-cetylase inhibitors, as HDAC enzymes have been reported to promote AD neurotoxicity.”
Self-citationPoirier, M., Awale, M., Roelli, M. A., Giuffredi, G. T., Ruddigkeit, L., Evensen, L., Stooss, A., Calarco, S., Lorens, J. B., Charles, R., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800554 · Cited by 20 · cited 1×
“Poirier et al. 2018 conducted an experiment using PPB for the identification of lysophosphatidic acid acyltransferase β as a therapeutic target of nanomolar angiogenesis, whereas Ozhathil et al. 2018 identified potent and selective small-molecule inhibitors of cation channel transient receptor…”
MethodWei, L., Wen, W., Rao, L., Huang, Y., Lei, M., Liu, K., Hu, S., Song, R., Ren, Y., & Wan, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01197 · Cited by 20 · cited 1×
“Herein a new protocol, called Cov_FB3D, has been devised, which involves the in silico assembly of potential novel covalent inhibitors by identifying the active fragments in the covalently binding site of the target protein [441].”
MethodBanegas‐Luna, A. J., Cerón‐Carrasco, J. P., Martín, S. P., & Pérez‐Sánchez, H. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00279 · Cited by 20 · cited 1×
“…www. rcidm. org/ Hybri dSim-VS/) [201], PKRank [202], PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc. eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/ rader/) [205], QEX [206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod…”
DrPOCS: Drug Repositioning Based on Projection Onto Convex Sets
Wang, Y., Cui, C., Qi, L., Yan, H., & Zhao, X. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2830384 · Cited by 20
Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach
Kubick, N., Pajares, M., Enache, I., Manda, G., & Mickael, M. (2020) · Molecules · doi:10.3390/molecules25092155 · Cited by 19 · cited 1×
“This novel approach has been proved to effective for reposition in NDDs [439].”
BackgroundChen, Y., Xie, J., Sun, Q., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4618 · Cited by 19 · cited 1×
“Further, chen et al. 2019 used the STITCH database to find targets of potential drugs short-listed for esophageal carcinoma [351].”
MethodUnifying machine learning and quantum chemistry -- a deep neural network for molecular wavefunctionsPreprint
Schütt, K. T., Gastegger, M., Tkatchenko, A., et al. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1906.10033 · Cited by 19 · cited 1×
“With these data, we can determine the electronic properties of molecules, the arrangement of chemical bonds around a molecule, and the location of reactive sites [78].”
BackgroundHow CUDA Powers the Machine Learning Revolution
Ilievski, A., Zdraveski, V., & Gušev, M. (2018) · Telecommunications Forum (TELFOR) · doi:10.1109/telfor.2018.8611982 · Cited by 18 · cited 1×
“In 2007 Nvidia introduced compute unified device architecture (CUDA), a framework that allowed programmers and researchers to use GPU for general purpose computing [31].”
MethodENRI: A tool for selecting structure‐based virtual screening target conformations
Akbar, R., Jusoh, S. A., Amaro, R. E., & Helms, V. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12900 · Cited by 17 · cited 1×
“…EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176], PL-PatchSurfer2 (http:// www. kihar alab. org/ plps2/) [177], SPOT-ligand 2 (http:// sparks-lab. org/) [178], Gypsum-DL (https:// durra ntlab. pitt. edu/ gypsum-dl/) [179], and ENRI [180] have been developed for SBVS.”
InfluentialQEX: target-specific druglikeness filter enhances ligand-based virtual screening
Mochizuki, M., Suzuki, S. D., Yanagisawa, K., et al. (2018) · Molecular Diversity · doi:10.1007/s11030-018-9842-3 · Cited by 16 · cited 1×
“…PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc. eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/ rader/) [205], QEX [206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod ockbi as. wordp ress. com/) [208], Ligity [209],…”
Kaiser, T. M., Dentmon, Z. W., Dalloul, C. E., Sharma, S. K., & Liotta, D. C. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00612 · Cited by 16 · cited 1×
“Similarly, [470] used a cascade of Naïve Bayes networks to find potent and safe abelson tyrosine-protein kinase 1 (c-Abl) inhibitors, which promote neuroprotection in PD. Likewise, Shao et al. 2018 used integration of SVM algorithm and Tanimoto similarity-based clustering, followed by in vitro…”
MethodProtein Binding Pocket Optimization for Virtual High-Throughput Screening (vHTS) Drug Discovery
Gazgalis, D., Zaka, M., Abbasi, B. H., Logothetis, D. E., Mezei, M., & Cui, M. (2020) · ACS Omega · doi:10.1021/acsomega.0c00522 · Cited by 16 · cited 1×
“However, SBVS is associated with the problem of an increasing number of disease-causing proteins and their complicated conformations [164].”
BackgroundArtificial Intelligence-Based Drug Design and Discovery
Lo, Y., Ren, G., Honda, H., & Davis, K. L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89012 · Cited by 16
Aggarwal, M., & Murty, M. N. (2020) · SpringerBriefs in applied sciences and technology · doi:10.1007/978-981-33-4022-0_3 · Cited by 15 · cited 1×
“DL is a subset of ML, which itself is a subset of AI, and thus, the evolution goes like AI > ML > DL [13, 14].”
BackgroundSPIDR: small-molecule peptide-influenced drug repurposing
King, M. D., Long, T., Pfalmer, D. L., Andersen, T., & McDougal, O. M. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2153-y · Cited by 15
Item response theory evaluation of the biomedical scale of the Pain Attitudes and Beliefs Scale
Chiarotto, A., Bishop, A., Foster, N. E., Duncan, K., Afolabi, E. K., Ostelo, R., & Paap, M. C. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202539 · Cited by 15
Investigation of Machine Intelligence in Compound Cell Activity Classification
Fan, Y., Zhang, Y., Hua, Y., Wang, Y., Zhu, L., Zhao, J., Yan, Y., Chen, X., Lü, S., Lu, T., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00558 · Cited by 14 · cited 2×
“For example, [65] distinguish compound cell activity using machine intelligence methods such as DT, random forest (RF) method, CNN, SVM, LSTM network, and gradient boosting machine.”
MethodResultPatel, R. D., Kumar, S. P., Pandya, H., & Solanki, H. (2018) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2018.1499840 · Cited by 14
Huang, K., Fu, T., Glass, L. M., et al. (2020) · arXiv (Cornell University) · Cited by 14
Ding, Q., Hou, S., Zu, S., Zhang, Y., & Li, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa187 · Cited by 13
GCAC: galaxy workflow system for predictive model building for virtual screening
Bharti, D. R., Hemrom, A. J., & Lynn, A. M. (2019) · BMC Bioinformatics · doi:10.1186/s12859-018-2492-8 · Cited by 13 · cited 1×
“…[206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod ockbi as. wordp ress. com/) [208], Ligity [209], D3Similarity (https:// www. d3pha rma. com/ D3Tar gets- 2019-nCoV/ D3Sim ilari ty/ index. php) [210], and GCAC (http:// ccbb. jnu. ac. in/ gcac) [211].”
RCDR: A Recommender Based Method for Computational Drug Repurposing
Sadeghi, S. S., & Keyvanpour, M. R. (2019) · International Conference on Knowledge-Based Engineering and Innovation · doi:10.1109/kbei.2019.8734933 · Cited by 13
Suzuki, S. D., Ohue, M., & Akiyama, Y. (2017) · Artificial Life and Robotics · doi:10.1007/s10015-017-0416-8 · Cited by 12
Ligity: A Non-Superpositional, Knowledge-Based Approach to Virtual Screening
Ebejer, J.-P., Finn, P. W., Wong, W. K., Deane, C. M., & Morris, G. M. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00779 · Cited by 12
Kalaiarasi, C., Manjula, S., & Kumaradhas, P. (2019) · RSC Advances · doi:10.1039/c9ra08607b · Cited by 11 · cited 1×
“However, sometimes with conventional computational techniques, quantum mechanics can be computationally very expensive and demanding, which can affect its accuracy [77].”
BackgroundTrends in Pattern Recognition and Machine Learning
Majumdar, D. D. (1985) · Defence Science Journal · doi:10.14429/dsj.35.6027 · Cited by 11 · cited 1×
“Some describe ML as the primary AI application, while others describe it as a subset of AI [11, 12].”
BackgroundTan, M., Amudi, K., Doğan, İ., et al. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10161-8 · Cited by 10 · cited 2×
“Srivastava et al. 2020 used admetSAR to evaluate the toxicity of Withania somnif-era as a therapeutic compound against COVID-19, whereas Uygun et al. 2021 incorporated pkCSM for the identification of the therapeutic effect and toxicological properties of pyrazolo[1,5-a]pyrazine-4(5H)-one derivative…”
BackgroundMethodRoy, K., Kar, S., & Das, R. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801505-6.00009-0 · Cited by 10
Pantuck, A. J., Lee, D., Kee, T. W., et al. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201870020 · Cited by 9
Roy, K., Kar, S., & Das, R. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801505-6.00012-0 · Cited by 8
Dr AFC : drug repositioning through anti-fibrosis characteristic
Wu, D., Gao, W., Xiao-yi, L., Tian, C., Jiao, N., Fang, S., Xiao, J., Xu, Z., Zhu, L., Zhang, G., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa115 · Cited by 8 · cited 2×
“The results concluded that natural products possess anti-fibrosis characteristics and serve as potential anti-fibrosis drug targets [284].”
BackgroundMethodIdentification of Target Genes at Juvenile Idiopathic Arthritis GWAS Loci in Human Neutrophils
Li, J., Yuan, X., March, M., Yao, X., Sun, Y., Chang, X., Hakonarson, H. H., Xia, Q., Meng, X., & Li, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00181 · Cited by 8 · cited 1×
“For instance, Li et al. [48] used the GWAS catalog, gene expression, epigenomics, and methylation data to determine target genes associated with juvenile idiopathic arthritis loci through ML analysis .”
MethodViceconti, M., HENNEY, A. M., & Morley‐Fletcher, E. (2016) · Cited by 8
Zhu, Q., Luo, J., Ding, P., et al. (2018) · Lecture notes in computer science · doi:10.1007/978-3-319-94968-0_2 · Cited by 8
Wang, M.-N., You, Z., Li, L., Chen, Z., & Xie, X.-J. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-60796-8_47 · Cited by 8 · cited 1×
“Another AI application in drug repurposing comes from the study performed by Wang et al. 2020, which used bipartite graph convolutional networks for in silico drug repurposing.”
MethodS, B. G. A., Prasana, J. C., & Muthu, S. (2020) · Materials Today Proceedings · doi:10.1016/j.matpr.2020.07.464 · Cited by 7
Prediction of K562 Cells Functional Inhibitors Based on Machine Learning Approaches
Zhang, Y., Han, Z., Gao, Q., Bai, X., Zhang, C., & Hou, H. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191107092214 · Cited by 7
Hermansyah, O., Bustamam, A., & Yanuar, A. (2020) · doi:10.21203/rs.2.22282/v1 · Cited by 7
[Elimination protocols in atopic dermatitis].
Jc, G. (1998) · PubMed · Cited by 7
Qi, Y., & Tang, Q. (2019) · Machine Learning for Healthcare Conference · Cited by 7
Predicting cancer-relevant proteins using an improved molecular similarity ensemble approach
Zhou, B., Sun, Q., & De, K. (2016) · Oncotarget · doi:10.18632/oncotarget.8716 · Cited by 6 · cited 1×
“In 2016, Huang et al. predicted the in vivo toxicity profile and mechanism characterization of more than 10,000 chemical compounds through modeling Tox21, whereas, in the same year, Zhou et al. predicted the cancer-relevant proteins using an improved molecular SEA [331, 332].”
Backgroundde Angelo, R. M., Io, A. K., Almeida, M. P., et al. (2020) · IEEE International Conference on Semantic Computing (ICSC) · doi:10.1109/icsc.2020.00042 · Cited by 6
Bioactive molecule prediction using majority voting-based ensemble method
Petinrin, O. O., & Saeed, F. (2018) · Journal of Intelligent & Fuzzy Systems · doi:10.3233/jifs-169596 · Cited by 5 · cited 1×
“Additionally, Petinrin et al. [139] used the majority voting technique with an ensemble of different machine learning models to determine biologically active molecules.”
DrugPathSeeker: Interactive UI for exploring drug-ADR relation via pathways
Verma, J., Luo, H., Hu, J., & Zhang, P. (2017) · IEEE Pacific Visualization Symposium · doi:10.1109/pacificvis.2017.8031602 · Cited by 5
Prediction of active compounds from SMILES codes using backpropagation algorithm
Ratnawati, D. E., Marjono, M., & Anam, S. (2018) · AIP conference proceedings · doi:10.1063/1.5062773 · Cited by 5
American Association for the Advancement of Science
Hale, W. H. (1913) · Scientific American · doi:10.1038/scientificamerican01181913-34supp · Cited by 4
PyGOLD: a python based API for docking based virtual screening workflow generation
Patel, H., Brinkjost, T., & Koch, O. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx197 · Cited by 4 · cited 1×
“…[199], Open-source platform [200], HybridSim-VS (http:// www. rcidm. org/ Hybri dSim-VS/) [201], PKRank [202], PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc. eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/ rader/) [205], QEX [206], IVS2vec (https:// github. com/…”
Jarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Research Square · doi:10.21203/rs.3.rs-56433/v1 · Cited by 4
MET: a Java package for fast molecule equivalence testing
Schüler, J., Rechner, S., & Müller‐Hannemann, M. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00480-1 · Cited by 4
LSA: a local-weighted structural alignment tool for pharmaceutical virtual screening
Li, X., Yan, X., Yang, Y., Gu, Q., Zhou, H., Du, Y., Lu, Y., Liao, J., & Xu, J. (2019) · RSC Advances · doi:10.1039/c8ra08915a · Cited by 3
A decision theoretic approach to model evaluation in computational drug discoveryPreprint
Watson, O. P., Cortés‐Ciriano, I., Taylor, A. R., & Watson, J. A. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1807.08926 · Cited by 3 · cited 1×
“…organic compounds with the help of computer programs, designing new compounds, developing assays, and predicting the 3D structure of target molecules are some time-consuming and tiresome tasks which with the help of AI can be reduced and can speed up the process of drug discovery [94, 95].”
Background(2015) · The Dictionary of Genomics, Transcriptomics and Proteomics · doi:10.1002/9783527678679.dg10319 · Cited by 2
S, B. G. A., Madaj, R., Sanker, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12423638.v3 · Cited by 2
A chemical language based approach for protein - ligand interaction prediction.Preprint
Öztürk, H., Özgür, A., & Özkırımlı, E. (2018) · arXiv (Cornell University) · Cited by 2
Jc, G. (1998) · PubMed · Cited by 2
PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative modelsPreprint
Born, J., Manica, M., Cadow, J., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.13285 · cited 1×
“Jiang et al. 2019, using DeepAffinity, proposed a novel protein descriptor for identifying drug-target interaction, whereas Born et al. 2020 with the help of Deep Affinity, identified antiviral candidates for SARS-CoV-2 [319, 320].”
Method
Research works printed but not linked: 5
- Carpenter KA, Huang X (2018) Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: a review. Curr Pharm Des. https://doi.org/10.2174/1381612824666180607124038 · DOI · Paper page
- Gad SC (2014) QSAR. In: Third E (ed) Wexler PBT- Encyclopedia of Toxicology. Academic Press, Oxford, pp 1–9
- Royal Society of Chemistry (2015) ChemSpider. Search and Share Chemistry. R. Soc, Chem
- Cao X, Fan R, Zeng W (2020) DeepDrug: a general graph-based deep learning framework for drug relation prediction. biorxiv. https://doi.org/10.1101/2020.11.09.375626 · DOI
- Harrer S, Shah P, Antony B, Hu J (2019) Artificial intelligence for clinical trial design. Trends Pharmacol Sci 40:577–591. https://doi.org/10.1016/j.tips.2019.05.005 · DOI · Paper page
Cited by
The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century
Maleki Varnosfaderani, S., & Forouzanfar, M. (2024) · Bioengineering · doi:10.3390/bioengineering11040337 · Cited by 931
“By analyzing historical data from clinical trials and patient records, AI models can predict the effectiveness of drugs on various demographic groups [44,45].”
MethodThe role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
“Today, AI-based technologies have been applied to virtually every step in the drug discovery process, including target identification, drug design, drug screening, chemical synthesis, and prediction of the drug’s properties and mode of action.(341,342) In addition, AI can be used to quickly identify lead compounds ext…”
Metaverse for Healthcare: A Survey on Potential Applications, Challenges and Future Directions
Chengoden, R., Victor, N., Huynh-The, T., Yenduri, G., Jhaveri, R. H., Alazab, M., Bhattacharya, S., Hegde, P., Maddikunta, P. K. R., & Gadekallu, T. R. (2023) · IEEE Access · doi:10.1109/access.2023.3241628 · Cited by 508
“Artificial intelligence (AI), also known as machine intelligence, focuses on the development and management of technology that can autonomously learn to make decisions and carry out tasks on behalf of humans [90].”
BackgroundClinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
“Machine-learning and AI technology have the potential to accelerate the process of drug development, reducing failure rates, and increasing the accuracy of predictions [20, 177].”
Background
Metadata
- Authors
- Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P.
- Affiliations
- Delhi Technological University (IN)
- Corresponding author
- Kumar, Pravir
- Venue
- Molecular Diversity
- Published
- 2021-04-12
- Volume
- 25
- Issue
- 3
- Pages
- 1315-1360
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- PMC
- PMC8040371
- OpenAlex
- W3153418506
- Semantic Scholar
- 29409efa04ac99ccf01d2a011d21d5d14e870000
- Cited by
- 1,473
- References
- 503
- Citations by year
- 2026: 221 · 2025: 438 · 2024: 397 · 2023: 272 · 2022: 113 · 2021: 31
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Diversity (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- artificial intelligence in drug discovery, deep learning, computer-aided drug design, virtual screening, structure-based virtual screening, ligand-based virtual screening, QSAR, pharmacophore modeling, drug repurposing, polypharmacology, toxicity prediction, generative adversarial networks, molecular docking, protein misfolding, biomarker development, drug release monitoring
- MeSH terms
- Machine Learning, Drug Development, Deep Learning, Big Data, Algorithms, Animals, Artificial Intelligence, Humans, Models, Molecular, Research Design, Drug Design, Quantitative Structure-Activity Relationship, Drug Discovery, Data Mining, Chemistry Techniques, Synthetic, Support Vector Machine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.